The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Guardant Health; Nanostring Technologies
Stock and Other Ownership Interests - Guardant Health; Nanostring Technologies
Honoraria - Guardant Health; NanoString Technologies
Travel, Accommodations, Expenses - Guardant Health; NanoString Technologies
Circulating tumor DNA profile in pancreatic ductal adenocarcinoma (PDAC) and potential targeted therapy.
 
Francis Esposito
No Relationships to Disclose
 
David Pesantez
No Relationships to Disclose
 
Laura Angelats
No Relationships to Disclose
 
Alberto Indacochea
No Relationships to Disclose
 
Joan Martinez-Vidal
No Relationships to Disclose
 
Alba Cochs
No Relationships to Disclose
 
Alexis Perez
No Relationships to Disclose
 
Pol Sole i Bentz
No Relationships to Disclose
 
Debora Moreno Fernandez
No Relationships to Disclose
 
Iris Faull
No Relationships to Disclose
 
Mary Luz Campillo
Employment - Guardant Health; NanoString Technologies
Stock and Other Ownership Interests - Guardant Health; NanoString Technologies
Honoraria - Guardant Health; NanoString Technologies
Travel, Accommodations, Expenses - Guardant Health; NanoString Technologies
 
Lidia Garcia-Losada
No Relationships to Disclose
 
Angélica Rodríguez
No Relationships to Disclose
 
Pilar Vicente
No Relationships to Disclose
 
Miguel Nogué
No Relationships to Disclose
 
Iván Victoria
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Tamara Sauri
No Relationships to Disclose
 
Javier García-Corbacho
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - BMS